뇌유래 신경성장인자(BDNF) : 파이프라인 리뷰

※ 본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

뇌유래 신경성장인자(Brain Derived Neurotrophic Factor)를 표적으로 한 치료제 개발 파이프라인 현황과 최신 업데이트에 의한 각 개발 단계 비교 분석, 기업과 연구기관이 개발중인 치료제, 치료제 평가, 후기 단계 및 중지된 프로젝트 관련 정보, 최신 뉴스와 발표 등의 정보를 전해드립니다.

서론

• 조사 범위

뇌유래 신경성장인자(BNDF) 개요

치료제 개발

• 개발중인 제품 : 개발 단계별
• 개발중인 제품 : 치료 영역별
• 개발중인 제품 : 증상별

파이프라인 제품 상황 개요

• 후기 단계 제품
• 초기 단계 제품

기업에서 개발중인 제품

대학/연구기관에서 개발중인 제품

치료제 평가

• 단독치료 제품/병용요법 제품별
• 작용기전별
• 투여 경로별
• 분자 종류별

치료제 개발 참여기업

• AudioCure Pharma GmbH
• ReCyte Therapeutics Inc

약제 개요

• AC-002
• CNB-001
• Gene Therapy to Activate BDNF for Parkinson's Disease
• smilagenin
• Stem Cell Therapy for Ischemic Stroke

휴지 상태인 프로젝트

주요 뉴스 및 프레스 릴리스

부록

도표

Summary:

Global Markets Direct's, 'Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016', provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.

The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope:

• The report provides a snapshot of the global therapeutic landscape for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)
• The report reviews Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics and enlists all their major and minor projects
• The report assesses Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted therapeutics

Reasons to buy:

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Brain Derived Neurotrophic Factor (Abrineurin or BDNF)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Brain Derived Neurotrophic Factor (Abrineurin or BDNF) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

• Table of Contents
  • List of Tables
  • List of Figures
• Introduction
  • Global Markets Direct Report Coverage
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) Overview
• Therapeutics Development
  • Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Stage of Development
  • Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Therapy Area
  • Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Indication
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Products Glance
  • Late Stage Products
  • Early Stage Products
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Companies
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Products under Development by Universities/Institutes
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Therapeutics Assessment
  • Assessment by Monotherapy/Combination Products
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Companies Involved in Therapeutics Development
  • AudioCure Pharma GmbH
  • ReCyte Therapeutics Inc
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Drug Profiles
  • AC-002 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • CNB-001 - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Gene Therapy to Activate BDNF for Parkinson's Disease - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • smilagenin - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
  • Stem Cell Therapy for Ischemic Stroke - Drug Profile
    • Product Description
    • Mechanism Of Action
    • R&D Progress
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Dormant Projects
• Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Featured News & Press Releases
  • Apr 10, 2015: Evidence of the efficacy of AC002
  • Mar 26, 2013: Phytopharm Provides Strategic Review Update On On-going Phase II Clinical Trial Of Cogane
  • Feb 18, 2013: Phytopharm Announces Results From Parkinson's Disease Clinical Trial Of Cogane
  • Dec 18, 2012: Phytopharm Provides Update On Clinical Development Of Cogane In Amyotrophic Lateral Sclerosis
  • Apr 18, 2012: Phytopharm Completes Patient Recruitment In CONFIDENT-PD Phase II Cogane Study To Treat Parkinson's Disease
  • Apr 18, 2012: Phytopharm's Confirmatory Data Supports Effectiveness Of Phytopharm's Cogane In Amyotrophic Lateral Sclerosis
  • Jan 16, 2012: Phytopharm's Cogane Demonstrates Positive Results In Amyotrophic Lateral Sclerosis Study
  • Sep 29, 2011: European Commission Grants Orphan Drug Status For Phytopharm's Cogane For Treatment Of Amyotrophic Lateral Sclerosis
  • Jul 28, 2011: Phytopharm's Cogane Receives FDA Orphan Drug Status
  • Nov 17, 2010: Phytopharm Initiates Phase II Study Of Cogane In Patients With Parkinson's Disease
  • Jun 14, 2010: Phytopharm Receives FDA Approval To Begin Phase II Clinical Trial Of Cogane
  • Apr 20, 2009: Phytopharm Announces the Commencement of Clinical Study of Cogane in Patients with Parkinson's disease
  • Jan 21, 2008: Phytopharm Announces $1.16 million Funding For Cogane
  • Jun 05, 2007: Phytopharm plc Presents Cogane Data At '11th International Congress Of Parkinson's Disease And Movement Disorders'
  • Nov 30, 2005: Phytopharm Announes That The Preliminary Trial Results Are Expected In December 2005
• Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Comparative Analysis by Late Stage Development, H2 2016
• Comparative Analysis by Early Stage Products, H2 2016
• Number of Products under Development by Companies, H2 2016
• Products under Development by Companies, H2 2016
• Number of Products under Investigation by Universities/Institutes, H2 2016
• Products under Investigation by Universities/Institutes, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Stage and Mechanism of Action, H2 2016
• Number of Products by Stage and Route of Administration, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016
• Pipeline by AudioCure Pharma GmbH, H2 2016
• Pipeline by ReCyte Therapeutics Inc, H2 2016
• Dormant Projects, H2 2016

List of Figures

• Number of Products under Development for, H2 2016
• Number of Products under Development by Therapy Area, H2 2016
• Number of Products under Development by Indication, H2 2016
• Assessment by Monotherapy/Combination Products, H2 2016
• Number of Products by Mechanism of Actions, H2 2016
• Number of Products by Stage and Mechanism of Actions, H2 2016
• Number of Products by Routes of Administration, H2 2016
• Number of Products by Stage and Routes of Administration, H2 2016
• Number of Products by Molecule Types, H2 2016
• Number of Products by Stage and Molecule Type, H2 2016